Validation of the Madrid Genotype Score to Predict Pathogenic Variants in U.S. Dilated Cardiomyopathy Patients

JACC Advances 2026 Open access

Read full text
Authors: Rebecca Resnick, Eric Y. Kao, Charles C. Maynard, Shiva Tabaghi, Andrew B. Stergachis, Babak Nazer, Kai‐Chun Yang
DOI: 10.1016/j.jacadv.2026.102648
Cited by: 0
References: 5

Abstract

C ontemporary guidelines provide a class IIa recommendation to consider genetic testing for patients with dilated cardiomyopathy (DCM); however, there is limited guidance regarding which patients should be tested.1 Identification of pathogenic variants can stratify risk for sudden cardiac death, inform family planning, and enable cascade screening of at-risk relatives.Although

Fields of Study & Subjects

Cardiomyopathy and Myosin Studies Genomics and Rare Diseases Cardiac electrophysiology and arrhythmias

Publication details

Journal / source
JACC Advances
Volume
5
Issue
4
Pages
102648–102648
Publication date
13 March 2026
Language
EN